^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Liposarcoma
    Drug:Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/19/2016
    Excerpt:
    HALAVEN is a microtubule inhibitor indicated for the treatment of patients with...Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    03/17/2011
    Excerpt:
    Halaven is indicated for the treatment of adult patients with unresectable liposarcoma…
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Soft Tissue Sarcoma: Preferred Regimens…Eribulin (category 1 recommendation for liposarcoma, category 2A for other subtypes)
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    Excerpt:
    Summary of recommendations...Eribulin is an option in patients with liposarcomas and LMS [II, A].
    DOI:
    10.1093/annonc/mdy310